News | December 14, 2025
Biocon Biologics strikes deal to sell its version of the eye drug Aflibercept worldwide
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The new centre brings advanced corneal procedures pioneered in India
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
While Merck can appeal, Halozyme said it expects the order to hold
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Subscribe To Our Newsletter & Stay Updated
